Delivery composition and method

• US 20040087564A1
• Filed: 10/31/2002
• Published: 05/06/2004
• Est. Priority Date: 10/31/2002
• Status: Abandoned Application

• Current Assignee: Novavax Inc.
• Original Assignee: Novavax Inc.
• Inventors: Mauk, John E., Wright, D. Craig
• Application Number:
  US10/284,465
• Publication Number:
  US 20040087564A1
• Time in Patent Office: Days
• US Class Current: 514/179
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence

Abstract

A composition which includes a membrane modulators is disclosed. The composition can be used in a wide range of therapies for delivering a membrane modulator which play an active function in regulating, controlling or causing a desired therapeutic effect to a target cell.

Claims

1. A composition comprising:

an emulsion comprising a hydrophobic phase and a hydrophilic phase, wherein the hydrophobic phase comprises;

a membrane modulator; and

a wall forming material.

2. The composition of claim 1 wherein the range of ratios of hydrophobic phase to hydrophilic phase comprises from about 1:

1.5 to about 11.5;

1.

3. The composition of claim 1 wherein the membrane modulator is a sterol.

4. The composition of claim 1 wherein the membrane modulator is a compound of the formula:

27. The composition of claim 1 wherein the membrane modulator is an animal sterol.

28. The composition of claim 1 wherein the membrane modulator is testosterone, progesterone, estrogen, cholesterol, dehydroepiandrosterone, fludrocortisone, or cortisol.

29. The composition of claim 1 wherein the membrane modulator is creatine, miconazole nitrate, aspirin, 2-metronidazole, or 5-metronidazole.

30. The composition of claim 1 wherein the membrane modulator is an antibiotic.

31. The composition of claim 1 wherein the membrane modulator is ciprofloxacin, cefuroxime, cefatrizine, celpodoxime, clarithromycin, loracarbef, azithromycin, cefixime, cefadroxil, amoxycillin, acyclovir, cyclosporin, cephalosporin or baclofen.

32. The composition of claim 1 wherein the membrane modulator is a plant sterol.

33. The composition of claim 32 wherein the plant sterol is a sterol.

34. The composition of claim 32 wherein the plant sterol is a stanol.

35. The composition of claim 32 wherein the membrane modulator is beta-sitostanol (24-ethyl-5 -cholestene-3 -beta-ol), beta-sitostanol (24-ethyl-5 -alpha-cholestane-3 -beta-ol), campesterol, brassicasterol or stigmasterol.

36. The composition of claim 1 wherein the membrane modulator is an amino acid.

37. The composition of claim 1 wherein the membrane modulator is a peptide.

38. The composition of claim 1 wherein the wall forming material is polyoxyethylene sorbitan ester, polyoxyethylene fatty acid ether or sorbitan monoester.

39. The composition of claim 1 wherein the hydrophobic phase comprises polyoxyethylene(20) sorbitan monooleate, stearyl alcohol, and testosterone.

40. The composition of claim 1 wherein the hydrophilic phase comprises an alcohol and water mixture.

41. The composition of claim 1 wherein the hydrophilic phase comprises water.

42. The composition of claim 1 wherein the hydrophilic phase comprises phosphate buffered saline.

43. The composition of claim 1 wherein the membrane modulator comprises a modified sterol.

44. The composition of claim 1 wherein the membrane modulator contains a ring structure.

45. The composition of claim 1 wherein the membrane modulator contains a multi-ring structure.

5. A composition comprising:

a non-Newtonian fluid comprising a hydrophobic phase in contact with a hydrophilic phase, wherein the hydrophobic phase comprises;

a biologically active compound; and

a wall forming material.

6. The composition of claim 5 wherein the biologically active compound is a sterol.

7. The composition of claim 5 wherein the biologically active compound is an animal sterol.

8. The composition of claim 5 wherein the biologically active compound is a plant sterol.

9. A composition comprising:

a non-Newtonian fluid comprising a hydrophobic phase in contact with a hydrophilic phase, wherein the hydrophobic phase comprises;

an amphiphile;

a biologically active compound; and

a wall forming material.

10. The composition of claim 9 wherein the amphiphile has a positive charge.

11. The composition of claim 9 wherein the amphiphile has a negative charge.

12. The composition of 9 wherein the amphiphile is a surfactant.

13. A composition comprising:

a non-Newtonian fluid comprising a hydrophobic phase in contact with a hydrophilic phase, wherein the hydrophobic phase comprises;

a surfactant;

a sterol; and

a wall forming material.

14. The composition of claim 13 wherein the sterol is estradiol, testosterone, progesterone, cholesterol, dehydroepiandrosterone, fludrocortisone, or cortisol.

15. A composition comprising:

a non-Newtonian fluid comprising a hydrophobic phase in contact with a hydrophilic phase, wherein the hydrophobic phase comprises;

a surfactant;

a membrane modulator;

a wall forming material; and

an oil.

16. The composition of claim 15 wherein the oil is soybean oil, avocado oil, squalene oil, sesame oil, olive oil, canola oil, mink oil, cotton seed oil, palm oil, corn oil, rapeseed oil, safflower oil, coconut oil, linseed oil, jojoba bean oil, palm oil, sunflower oil, fish oils, wheat germ oil, almond oil, apricot seed oil, macadamia nut oil or peanut oil.

17. A composition comprising:

a non-Newtonian fluid comprising a hydrophobic phase in contact with a hydrophilic phase, wherein the hydrophobic phase comprises;

a surfactant;

a membrane modulator; and

a charge source.

18. The composition of claim 17 wherein the membrane modulator is a sterol.

19. The composition of claim 17 wherein the membrane modulator is an animal sterol.

20. The composition of claim 17 wherein the membrane modulator is a plant sterol.

21. The composition of claim 17 wherein the charge source has a positive charge.

22. The composition of claim 17 wherein the charge source has a negative charge.

23. The composition of claim 17 wherein the membrane modulator is an antibiotic.

24. The composition of claim 17 wherein the membrane modulator is an amino acid.

25. The composition of claim 17 wherein the membrane modulator is a peptide.

26. The composition of claim 17 wherein the surfactant is polyoxyethylene sorbitan ester, polyoxyethylene fatty acid ether or sorbitan monoester.

46. The composition of 1 wherein the membrane modulator is a drug.

47. A method of making a composition comprising liquefying a hydrophobic phase and mixing the hydrophobic phase with a hydrophilic phase to form a non-Newtonian fluid including a membrane modulator.

48. The method of 47 wherein the liquefying comprises melting.

49. The method of 47 wherein the mixing is accomplished using a high shear mixer.

50. The method of 47 wherein the hydrophobic phase is liquefied to form a slurry.

51. The method of 47 wherein the hydrophilic phase is added to the hydrophobic phase while mixing.

52. The method of 47 wherein the hydrophobic phase is added to the hydrophilic phase while mixing.

53. The method of 47 wherein the hydrophobic phase comprises:

a membrane modulator; and

a wall forming material.

56. The composition of claim 53 wherein the wall forming material is polyoxyethylene sorbitan ester, polyoxyethylene fatty acid ether or sorbitan monoester.

54. The method of 53 wherein the membrane modulator is a animal sterol, plant sterol, antibiotic, amino acid, drug or peptide.

55. The composition of claim 54 wherein the membrane modulator is testosterone, progesterone, estrogen, cholesterol, dehydroepiandrosterone, fludrocortisone, or cortisol.

57. A method of delivering a biologically active molecule comprising:

providing a composition comprising a hydrophobic phase and a hydrophilic phase, wherein the hydrophobic phase comprises a membrane modulator and a wall forming material; and

contacting the composition with a human body.

58. The method of 57 wherein contacting includes transdermal delivery.

59. The method of 57 wherein contacting includes intramuscular delivery.

60. The method of 57 wherein contacting includes subcutaneous delivery.

61. The method of 57 wherein contacting includes mucosal delivery.

62. The method of 57 wherein contacting includes oral delivery.

63. The method of 57 wherein contacting includes intravenous delivery.

64. The method of 57 wherein contacting includes time release delivery.

65. The method of 57 wherein contacting includes delivery through a needle having a 25 gauge or thinner bore needle.